BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 10803528)

  • 1. Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay.
    M'soka TJ; Nishioka J; Taga A; Kato K; Kawasaki H; Yamada Y; Yu A; Komada Y; Nobori T
    Leukemia; 2000 May; 14(5):935-40. PubMed ID: 10803528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent Loss of Methylthioadenosine Phosphorylase (MTAP) in Primary Cutaneous T-Cell Lymphoma.
    Woollard WJ; Kalaivani NP; Jones CL; Roper C; Tung L; Lee JJ; Thomas BR; Tosi I; Ferreira S; Beyers CZ; McKenzie RCT; Butler RM; Lorenc A; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2016 Jun; 136(6):1238-1246. PubMed ID: 26872600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
    Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
    Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts.
    Xie H; Rachakonda PS; Heidenreich B; Nagore E; Sucker A; Hemminki K; Schadendorf D; Kumar R
    Oncotarget; 2016 Mar; 7(13):16490-504. PubMed ID: 26909863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.
    Tedeschi PM; Kathari YK; Johnson-Farley N; Bertino JR
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1247-52. PubMed ID: 25917288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of dinucleotide repeat (Delta 14 allele) in the methylthioadenosine phosphorylase (MTAP) promoter and the allelotype of MTAP promoter in the Japanese population.
    Kadariya Y; Nishioka J; Nakatani K; Nakashima K; Nobori T
    Jpn J Cancer Res; 2002 Apr; 93(4):369-73. PubMed ID: 11985785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and Prognostic Significance of Methylthioadenosine Phosphorylase Deficiency in Nasopharyngeal Carcinoma.
    He HL; Lee YE; Shiue YL; Lee SW; Chen TJ; Li CF
    Medicine (Baltimore); 2015 Dec; 94(49):e2271. PubMed ID: 26656376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
    Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
    Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of expression of MTAP in uncommon T-cell lymphomas.
    Bertino JR; Lubin M; Johnson-Farley N; Chan WC; Goodell L; Bhagavathi S
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):306-9. PubMed ID: 23040436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylthioadenosine phosphorylase inactivation depends on gene deletion in laryngeal squamous cell carcinoma.
    Conde L; Vilaseca I; Alós L; Bernal-Sprekelsen M; Cardesa A; Nadal A
    Histopathology; 2012 Dec; 61(6):1082-8. PubMed ID: 23020581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance.
    Li CF; Fang FM; Kung HJ; Chen LT; Wang JW; Tsai JW; Yu SC; Wang YH; Li SH; Huang HY
    Oncotarget; 2014 Nov; 5(22):11428-41. PubMed ID: 25426549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
    de Oliveira SF; Ganzinelli M; Chilà R; Serino L; Maciel ME; Urban Cde A; de Lima RS; Cavalli IJ; Generali D; Broggini M; Damia G; Ribeiro EM
    PLoS One; 2016; 11(1):e0145647. PubMed ID: 26751376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of MTAP immunohistochemical deficiency with CDKN2A homozygous deletion and clinicopathological features in pleomorphic xanthoastrocytoma.
    Lou L; Li J; Qin M; Tian X; Guo W; Li Y
    Brain Tumor Pathol; 2023 Jan; 40(1):15-25. PubMed ID: 36550382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
    Gundogdu F; Babaoglu B; Soylemezoglu F
    J Neuropathol Exp Neurol; 2024 Jan; 83(2):107-114. PubMed ID: 38109891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression.
    Liu W; Zhuang C; Huang T; Yang S; Zhang M; Lin B; Jiang Y
    Mol Genet Genomic Med; 2020 Dec; 8(12):e1521. PubMed ID: 33155773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
    Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
    Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?
    Nishikubo M; Jimbo N; Tanaka Y; Tachihara M; Itoh T; Maniwa Y
    Virchows Arch; 2022 Aug; 481(2):307-312. PubMed ID: 35043235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
    Barekatain Y; Ackroyd JJ; Yan VC; Khadka S; Wang L; Chen KC; Poral AH; Tran T; Georgiou DK; Arthur K; Lin YH; Satani N; Ballato ES; Behr EI; deCarvalho AC; Verhaak RGW; de Groot J; Huse JT; Asara JM; Kalluri R; Muller FL
    Nat Commun; 2021 Jul; 12(1):4228. PubMed ID: 34244484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.